DKSH has entered an agreement with Stilla Technologies in Asia. This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market.
Singapore, June 1, 2022– DKSH Business Unit Technology has entered a partnership with Stilla Technologies, one of the world’s leading Digital PCR manufacturers. DKSH will provide marketing and sales, application support, and after-sales services in Australia, Malaysia, New Zealand, and the Philippines.
Having taken digital PCR to a whole new level, Stilla Technologies makes absolute quantification of multiple genetic markers and multiple tests from a single sample possible for researchers across a breadth of applications. From quantifying ctDNA in liquid biopsies for oncology, to detecting low-level genetic variants in infectious diseases, dPCR is allowing researchers to parse complex genomics data to gain real-world, actionable genetic insights at both the patient and the population level. Their high-sensitivity 6-color naica® system is the world’s most powerful digital PCR platform, offering the highest multiplexing capability on the market.
“DKSH has a strong regional footprint and market access. With their focus and expertise in the life sciences segment and digital PCR, we are confident that DKSH is the trusted partner to help us expand the markets and meet our growth goals,” said Matt Grow, PhD, Vice President/ Global Commercial Operations, Stilla Technologies.
Marco Farina, Senior Director, Business Development, Business Unit Technology, commented: “With the partnership with Stilla Technologies, DKSH gets a very strong product in the genomics area that will benefit many of our existing customers in the life sciences@ segment. We are confident to grow the market, leveraging our good sales coverage, strong application support, and excellence in after-sales services. DKSH will continuously provide our customers with innovative solutions that improve their research.
About Stilla Technologies
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website at https://www.stillatechnologies.com/ and connect on Twitter @StillaTech
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. www.dksh.com